Protein aggregation is linked to variety of neurodegenerative disorders and other diseases. Current research involves understanding the mechanism of protein aggregation, inhibiting protein aggregation under intra/extracellular space, lowering toxicity arising due to soluble oligomers, and augmenting the clearance of protein aggregates from the brain. Toward this direction, different types of antiamyloidogenic small molecules, macromolecules, and nanomaterials are identified that can inhibit protein aggregation, and extensive progress has been made for their effective utilization. Here, we summarize our effort in designing a nanoparticle form of antiamyloidogenic molecules with enhanced performance under in vitro and in vivo conditions. We found that the nanoparticle form of antiamyloidogenic molecules can perform up to 100,000-times better than the respective molecular form due to the combined effect of enhanced bioavailability at intra/extracellular space and multivalent binding property with aggregating protein. This work demonstrates that further research should be directed toward designing nanoparticle forms of antiamyloidogenic molecules for their effective performance.

中文翻译：

---

基于抗淀粉样蛋白的化学/生物化学设计的纳米颗粒作为人工伴侣，可有效抑制蛋白质聚集

蛋白质聚集与多种神经退行性疾病和其他疾病有关。当前的研究包括了解蛋白质聚集的机制，抑制细胞内/细胞外空间下的蛋白质聚集，降低由于可溶性低聚物引起的毒性以及增加蛋白质聚集物从大脑中的清除。朝着这个方向，已经确定了可以抑制蛋白质聚集的不同类型的产生抗淀粉样蛋白的小分子，大分子和纳米材料，并且其有效利用已经取得了广泛的进展。在这里，我们总结了我们在设计纳米淀粉形式的抗淀粉样蛋白形成分子方面的努力，这些分子在体外和体内条件下均具有增强的性能。我们发现，抗淀粉样蛋白形成分子的纳米颗粒形式最多可以执行100次，由于在细胞内/细胞外空间增强的生物利用度以及聚集蛋白的多价结合特性的综合作用，因此比各自的分子形式好000倍。这项工作表明，应进一步研究针对其有效性能而设计的抗淀粉样蛋白形成分子的纳米颗粒形式。